Pular para o conteúdo principal
Ranking Invest

RIGL - Rigel Pharmaceuticals, Inc.

Segmento: HealthcareRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valor de Mercado
$ 952.67 Mi
IVR
0.83Índice proprietário de comparação relativa: 0,83.
IVR2
0.38Leitura proprietária complementar: 38%.
MLL
0.38Leitura proprietária complementar: 38%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 425.42 Mi

Dívida Líquida

-$ 60.82 Mi

L4T

$ 321.91 Mi

MM4T

115.22%

Indicadores Básicos

ROE

75.67%

Índices de Previsibilidade

Receita Líquida

E0.20

Lucro

D0.85

Margem

E1.32

Índices de Tendência

Receita Líquida

B10.33

Lucro

A9.14

Margem

A9.49

Índices de Endividamento

DIV/PAT

-0.14

DIV/L4T

-0.19

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.